ASLAN Pharmaceuticals' involvement in a panel discussion on Atopic Dermatitis indicates its active role in the field. However, it's uncertain how this event will directly impact the company's stock performance in the short term. It could potentially raise its profile in the industry, but the effect on the stock price will depend on the outcomes and reception of the discussion.